Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03611946
Other study ID # CIR 318
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 6, 2018
Est. completion date March 18, 2022

Study information

Verified date March 2022
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection.


Description:

This study will evaluate the safety, reactogenicity, and immunogenicity of a single dose of the live attenuated Zika vaccine rZIKV/D4Δ30-713 in adults with no history of previous flavivirus infection. Participants will be randomly assigned to receive a single dose of either rZIKV/D4Δ30-713 or placebo at study entry (Day 0). Study visits will occur on Days 0, 4, 6, 8, 10, 12, 14, 16, 21, 28, 56, 90, 150, and 180. Visits may include a physical examination; blood, urine, saliva, nasopharyngeal (NP) or midturbinate swab, vaginal secretions, and semen collection; and pregnancy testing. SARS-CoV-2 PCR (nasopharyngeal or mid-turbinate swab) will be performed during screening and on days 0, 8, and 14.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date March 18, 2022
Est. primary completion date March 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Adult male or female between 18 and 50 years of age, inclusive. - Good general health as determined by physical examination, laboratory screening, and review of medical history. - Available for the duration of the study, which is approximately 26 weeks. - Willingness to participate in the study as evidenced by signing the informed consent document. - Females only: Female subjects of childbearing potential, with the exception noted below, should be willing to use effective contraception and have no plans to undergo IVF (in vitro fertilization) during participation in the trial. Reliable methods of contraception include hormonal birth control, condoms with spermicide, diaphragm with spermicide, surgical sterilization, and intrauterine device. Women must have been on an effective method of birth control for at least 30 days prior to enrollment. All female subjects will be considered as having childbearing potential, except for women who exclusively have sex with women, those who have had a hysterectomy, tubal ligation, or tubal coil (at least 3 months prior to vaccination), or are considered to be post-menopausal, as documented by at least 1 year since last menstrual period with a follicle-stimulating hormone (FSH) level in the menopausal range or at least 24 consecutive months of amenorrhea. Transgender men who have internal female organs and have sex with men will be considered of childbearing potential and should be willing to use effective contraception during the trial. Exception: Females who have sex with females (exclusively) and have no intention of conceiving a child during the study and women whose partners have had a vasectomy will not be required to use contraception, however they will be required to use female condoms and/or dental dams for at least 1 month following vaccination. For women whose sexual partner has had a vasectomy, the vasectomy must have been performed 30 days or more prior to enrollment. - Males only: Males of reproductive potential should be willing to use barrier contraception for the first 3 months following vaccination* and agree to not donate sperm for the duration of the study. - Based on CDC guidance for men returning from ZIKV-endemic areas Exclusion Criteria: - Females only: Currently pregnant, as determined by positive ß-human choriogonadotropin (HCG) test, or breast-feeding. - Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease based on history, physical examination, and/or laboratory studies. - Behavioral, cognitive, or psychiatric disease that, in the opinion of the investigator, affects the subject's ability to understand and cooperate with the requirements of the study protocol. - Screening laboratory values of Grade 1 or above for absolute neutrophil count (ANC), alanine aminotransferase (ALT), and serum creatinine, as defined in this protocol. - Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of a subject participating in the trial, or would render the subject unable to comply with the protocol. - Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by subject history. - History of a severe allergic reaction or anaphylaxis. - Severe asthma (emergency room visit or hospitalization within the last 6 months). - HIV infection, as indicated by screening and confirmatory assays. - Hepatitis C virus (HCV) infection, as indicated by screening and confirmatory assays. - Hepatitis B virus (HBV) infection, as indicated by hepatitis B surface antigen (HBsAg) screening. - Any known immunodeficiency syndrome. - History of Guillain-Barrè syndrome. - Current use of anticoagulant medications (this does not include anti-platelet medication such as aspirin or non-steroidal anti-inflammatory medications). - Use of immunosuppressive corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 28 days prior to or following inoculation. An immunosuppressive dose of corticosteroids is defined as greater than or equal to 10 mg of a prednisone equivalent per day for greater than or equal to 14 days. - Receipt of a live vaccine within 28 days or a killed vaccine within 14 days prior to inoculation, or anticipated receipt of any vaccine during the 28 days following inoculation with the exception of COVID-19 vaccines either licensed or under EUA which can be given at any time, however all effort will be made to avoid giving COVID-19 vaccines within the above windows. - Asplenia. - Receipt of blood products within the past 6 months, including transfusions or immunoglobulin, or anticipated receipt of any blood products or immunoglobulin during the 28 days following inoculation. - History or serologic evidence of previous ZIKV or other flavivirus infection (e.g., dengue, yellow fever virus, St. Louis Encephalitis virus, or West Nile virus). - Previous receipt of a flavivirus vaccine (licensed or experimental). - Receipt or anticipated receipt of any investigational agent in the 28 days before or after inoculation with the exception of COVID-19 vaccines, either licensed or authorized under EUA. - Refusal to allow specimen storage for future research. - Is in isolation or quarantine for SARS-CoV-2 infection or exposure and cannot complete screening or enrollment for this reason.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
rZIKV/D4?30-713 (Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection)
Administered at a dose of 10^3 plaque-forming units (PFUs) by subcutaneous injection
Placebo
Administered by subcutaneous injection.
rZIKV/D4?30-713 (Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection).
Administered at a dose of using 10^4 plaque-forming units (PFUs) by subcutaneous injection.

Locations

Country Name City State
United States Johns Hopkins University, Bloomberg School of Public Health Baltimore Maryland
United States University of Vermont Medical Center (UVMMC), Clinical Research Center Burlington Vermont

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of solicited local and general adverse events (AEs) Evaluated using the Adverse Event Grading Table in the study protocol Measured through Day 28
Primary Frequency of unsolicited AEs Evaluated using the Adverse Event Grading Table in the study protocol Measured through Day 28
Primary Frequency of medically-attended AEs and serious adverse events (SAEs) Evaluated using the Adverse Event Grading Table in the study protocol Measured through Day 90
Primary Peak neutralizing antibody titer to ZIKV with either 103 PFU or 104 PFU of rZIKV/D4?30 Determined by seropositivity and seroconversion frequencies Measured through Day 90
Secondary Frequency of viremia Measured by tissue culture (infectious virus) and PCR Measured through Day 180
Secondary Determination of the neutralizing antibody titer to ZIKV Determined by seropositivity and seroconversion frequencies Measured through Day 180
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04182685 - Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
Enrolling by invitation NCT04398901 - Neurodevelopmental Outcomes in ZIKV-Exposed Children
Completed NCT02996890 - Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) Phase 1
Completed NCT03188731 - ZIKAlliance Pregnant Women Cohort
Completed NCT03110770 - VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Phase 2
Active, not recruiting NCT04917861 - A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas Phase 2
Completed NCT02794181 - Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT04064905 - Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Phase 1
Completed NCT03106714 - Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
Completed NCT02979938 - Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection
Recruiting NCT03227601 - Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome N/A
Completed NCT03393286 - ZIKAlliance Children Cohort (ZIKAllianceCH)
Completed NCT03425149 - Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults Phase 1
Recruiting NCT05123222 - Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) Phase 1
Completed NCT02733796 - Persistence of Zika Virus in Semen After Acute Infection
Completed NCT03014089 - Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects Phase 1
Completed NCT03263195 - Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
Withdrawn NCT03204409 - ZIKAlliance Natural History Study